USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: American Biotechnology Co
Address: 7658 Standish Pl - Ste 107
Rockville, MD 20855
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $248,122.00 5
SBIR Phase II $495,000.00 1

Award List:

THE GOAL OF THIS PROJECT WILL BE TO SCREEN NEW DERIVATIVES OF L-ASCORBIC ACID ADDUCTS CLASSIFIED AS METHYLFURYLBUTYROLACTONES, ALSO REFERRED TO AS NAFOCARE B.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert w. veltri , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The goal of this project will be to screen new derivatives of l-ascorbic acid adducts classified as methylfurylbutyrolactones, also referred to as nafocare b. working in collaboration with a synthetic organic chemistry group at west virginia university, we have determined that the parent compound,… More

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael w. baseler , PRINCIPAL INVESTIGATOR
Award Amount: $49,593.00
Abstract:
And its potential application to human hybridoma technology.this project involves determining the ability of a new class of synthetic biological response modifiers (brm) known as methylfurylbutyrolactones (mfbl) to augment the production of lymphokines (il-2, b-cell growth factor, and immune… More

ALTHOUGH INVESTIGATION INTO BIOLOGICAL RESPONSE MODIFIERS HAS INCREASED RECENTLY, MOST OF THE EFFORT HAS BEEN TOWARDS POTENTIATING THE HOST'S CELL-MEDIATED IMMUNITY.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter e. maxim , PRINCIPAL INVESTIGATOR
Award Amount: $48,529.00
Abstract:
Although investigation into biological response modifiers has increased recently, most of the effort has been towards potentiating the host's cell-mediated immunity. data accumulated by our laboratories indicate that the methylfurylbutyrolactone (mfbl) class of compounds represents new synthetic… More

INTERFACE

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert w veltri , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
A major objective of this study is to investigate the utility of a new and innovative liquid microcarrier (mc) system for cloning and propagating human tumor cells in vitro. this new patented technology is an oil emulsion of defined droplet size (100 to 200 mm) having a smooth, pliable, and… More

EVALUATION OF THE IMMUNE MODULATOR MFBL FOR ANTIVIRAL EFFICACY

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency / Branch: DOD / NAVY
Principal Investigator: Dr Peter E Maxim
Award Amount: $50,000.00

EVALUATION OF THE IMMUNE MODULATOR MFBL FOR ANTIVIRAL EFFICACY

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency / Branch: DOD / NAVY
Principal Investigator: Dr Peter E Maxim
Award Amount: $495,000.00
Abstract:
The methylfurylbutyrolactones (mfbl's) are a unique group of chemical compounds that comprise a new group of synthetic immunomodulators. the compounds are water soluble, relatively non-toxic, economical to produce in quantity, and effective when administered via the intravenous, intraperitoneal or… More